Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

Lakshmikanth Katragadda, MD, Lindsay McCullough, MD, Yunfeng Dai, PhD, Jack W Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Maxim Norkin, MD PhD, Randy A Brown, MD, John R. Wingard, MD, Myron Chang, PhD, Jan S Moreb, MD

Blood (2015) 126 (23): 1988.

https://doi.org/10.1182/blood.V126.23.1988.1988

Published: 2015

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Lakshmikanth Katragadda, MD, Maxim Norkin, MD PhD, Myron Chang, PhD, Yunfeng Dai, PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Helen Leather, BPharm, Ying Li, MD PhD, Lamis K Eldjerou, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2015) 126 (23): 3221.

https://doi.org/10.1182/blood.V126.23.3221.3221

Published: 2015

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Lakshmikanth Katragadda, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1687.

https://doi.org/10.1182/blood.V120.21.1687.1687

Published: 2012

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, Lakshmikanth Katragadda, MD, Gabriela Rondon, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2001.

https://doi.org/10.1182/blood.V120.21.2001.2001

Published: 2012

Journal Articles

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

Lakshmikanth Katragadda, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Alessandra Ferrajoli, M.D., Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, M.D., Ph.D., Manoj Maniar, PhD, Francois Wilhelm, MD, PhD., Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3606.

https://doi.org/10.1182/blood.V120.21.3606.3606

Published: 2012

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

NARROW

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only